



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

COL9A2 (m): 293T Lysate: sc-125159

BACKGROUND

The extensive family of COL gene products (collagens) is composed of several chain types, including fibril-forming interstitial collagens (types I, II, III and V) and basement membrane collagens (type IV), each type containing multiple isoforms. Collagens are fibrous, extracellular matrix proteins with high tensile strength and are the major components of connective tissue, such as tendons and cartilage. All collagens contain a triple helix domain and frequently show lateral self-association in order to form complex connective tissues. Several collagens also play a role in cell adhesion, important for maintaining normal tissue architecture and function. COL9A2 (collagen α -2(IX) chain), also known as MED or EDM2, is a 689 amino acid extracellular matrix protein and component of hyaline cartilage and vitreous of the eye. A member of the fibril-associated collagens with interrupted helices (FACIT) family, COL9A2 is encoded by a gene that maps to human chromosome 1p34.2. Mutations in the COL9A2 gene are linked to multiple epiphyseal dysplasia.

REFERENCES

1. McCarthy, J.B., Vachhani, B. and Iida, J. 1996. Cell adhesion to collagenous matrices. *Biopolymers* 40: 371-381.
2. Cremer, M.A., Rosloniec, E.F. and Kang, A.H. 1998. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. *J. Mol. Med.* 76: 275-288.
3. Pihlajamaa, T., Vuoristo, M.M., Annunen, S., Perälä, M., Prockop, D.J. and Ala-Kokko, L. 1998. Human COL9A1 and COL9A2 genes. Two genes of 90 and 15 kb code for similar polypeptides of the same collagen molecule. *Matrix Biol.* 17: 237-241.
4. Alberio, L. and Dale, G.L. 1999. Review article: platelet-collagen interactions: membrane receptors and intracellular signalling pathways. *Eur. J. Clin. Invest.* 29: 1066-1076.
5. Boskey, A.L., Wright, T.M. and Blank, R.D. 1999. Collagen and bone strength. *J. Bone Miner. Res.* 14: 330-335.
6. Annunen, S., Paassilta, P., Lohiniva, J., Perälä, M., Pihlajamaa, T., Karppinen, J., Tervonen, O., Kröger, H., Lähde, S., Vanharanta, H., Ryhänen, L., Göring, H.H., Ott, J., Prockop, D.J. and Ala-Kokko, L. 1999. An allele of COL9A2 associated with intervertebral disc disease. *Science* 285: 409-412.
7. Czarny-Ratajczak, M., Lohiniva, J., Rogala, P., Kozłowski, K., Perälä, M., Carter, L., Spector, T.D., Kolodziej, L., Seppänen, U., Glazar, R., Królewski, J., Latos-Bielenska, A. and Ala-Kokko, L. 2001. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. *Am. J. Hum. Genet.* 69: 969-980.
8. Fiedler, J., Stöve, J., Heber, F. and Brenner, R.E. 2002. Clinical phenotype and molecular diagnosis of multiple epiphyseal dysplasia with relative hip sparing during childhood (EDM2). *Am. J. Med. Genet.* 112: 144-153.
9. Nakashima, E., Ikegawa, S., Ohashi, H., Kimizuka, M. and Nishimura, G. 2005. Double-layered patella in multiple epiphyseal dysplasia is not exclusive to DTDST mutation. *Am. J. Med. Genet.* A 133A: 106-107.

CHROMOSOMAL LOCATION

Genetic locus: Col9a2 (mouse) mapping to 4 D2.2.

PRODUCT

COL9A2 (m): 293T Lysate represents a lysate of mouse COL9A2 transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

COL9A2 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive COL9A2 antibodies. Recommended use: 10-20 μ l per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

COL9A2 (H-8): sc-398130 is recommended as a positive control antibody for Western Blot analysis of enhanced mouse COL9A2 expression in COL9A2 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



COL9A2 (H-8): sc-398130. Western blot analysis of COL9A2 expression in non-transfected: sc-117752 (A) and mouse COL9A2 transfected: sc-125159 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.